Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels

Inclusion Criteria: * Performance status ECOG-WHO 0 or 1 * Histologically proved metastatic colorectal adenocarcinoma, with non-resectable metastases * Adequate hematological, hepatic, and renal functions * Signed written informed consent Exclusion Criteria: * Previous treatment (chemotherapy, targeted therapy, surgery) for metastatic disease * History of autoimmune disease * Acute infectious disease * Known hypersensitivity grade 3-4 or contraindication to any of the study drugs * Patient with any medical or psychiatric condition or disease which would make the patient inappropriate for entry into this study. * Bevacizumab contraindication * Brain metastases * Other malignancy within the last 2 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer. * Pregnancy, breast-feeding or absence of adequate contraception for fertile patients * Patient under guardianship, curator or under the protection of justice.